Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

{{facet.display}}

{{facet.count}}

{{facet.count}}

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for "ORPHAN DRUG|Designated/Approved|Treatment of stage IIb to IV melanoma" in comments (approximate match)

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

RELATLIMAB

AF75XOF6W3

Subunit 1 (446) Similarity Search Subunit 2 (446) Similarity Search Subunit 3 (214) Similarity Search Subunit 4 (214) Similarity Search

Sequence Search

Subunit 1 (446) Similarity Search Subunit 2 (446) Similarity Search Subunit 3 (214) Similarity Search Subunit 4 (214) Similarity Search

Status:

US Approved Rx (2022)

Source:

BLA761234

(2022)

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761234

First approved in 2022

Source:

BLA761234

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761234

Class:

PROTEIN

NIVOLUMAB

31YO63LBSN

Subunit 1 (440) Similarity Search Subunit 2 (440) Similarity Search Subunit 3 (214) Similarity Search Subunit 4 (214) Similarity Search

Sequence Search

Subunit 1 (440) Similarity Search Subunit 2 (440) Similarity Search Subunit 3 (214) Similarity Search Subunit 4 (214) Similarity Search

Status:

US Approved Rx (2014)

Source:

BLA125554

(2014)

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554

First approved in 2014

Source:

BLA125554

Source URL:

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125554

Class:

PROTEIN

Protein

Protein

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1